Trial · NCT07896226
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | STAT-10 Score | Day 2 (the day after enrollment) | Sore Throat Assessment Tool-10 (STAT-10), a disease-specific patient-reported outcome measure. Ten items, each rated from 1 (not at all) to 5 (to a very high degree); total score range 10-50, with higher scores indicating greater symptom burden. Assessed in the acute tonsillitis (AT) and peritonsillar phlegmon (PP) groups. |
| Primary | PTAAT-12 Score | Day 2 (the day after enrollment) | Peritonsillar Abscess Assessment Tool-12 (PTAAT-12), a disease-specific patient-reported outcome measure. Twelve items, each rated from 1 (not at all) to 5 (to a very high degree); total score range 12-60, with higher scores indicating greater symptom burden. Assessed in the peritonsillar abscess (PTA) group. |
| Primary | Time to Symptom Resolution | From enrollment until reported recovery (daily questionnaire, days 1-7) | Time from enrollment to the first day on which the participant reports feeling recovered in the daily electronic questionnaire. All patients (AT, PP, and PTA groups). |
| Secondary | VAS Pain Score | Day 2 (the day after enrollment) | Throat pain measured on a Visual Analogue Scale (VAS) from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate more pain (worse outcome). Reported as: (a) average pain during the day, (b) maximum pain during the day, (c) minimum pain during the day, and (d) current pain. All patients (AT, PP, and PTA groups). |
| Secondary | Use of Analgesics | Days 1-7 (collectively) | Total consumption of the standardized as-needed analgesics (paracetamol and ibuprofen) during days 1-7. All patients (AT, PP, and PTA groups). |
| Secondary | Accumulated PTAAT-12 Score | Days 1-7 (collectively) | Sum of daily PTAAT-12 scores during days 1-7 (each daily score 12-60; higher scores indicate greater symptom burden). Peritonsillar abscess (PTA) group. |
| Secondary | Accumulated STAT-10 Score | Days 1-7 (collectively) | Sum of daily STAT-10 scores during days 1-7 (each daily score 10-50; higher scores indicate greater symptom burden). Acute tonsillitis (AT) and peritonsillar phlegmon (PP) groups. |
| Secondary | Complications | From enrollment to 14 days follow-up | Occurrence of complications within 14 days of inclusion. AT and PP groups: hospital admission, abscess formation, and spread of infection. PTA group: hospital admission, tonsillectomy, and spread of infection. |
| Secondary | TOI-14 Score | At 6 and 12 months follow-up, respectively | Tonsillectomy Outcome Inventory-14 (TOI-14), a patient-reported questionnaire on throat-related symptoms and their consequences during the preceding 6 months. Fourteen items, each rated on a 6-point scale from 'no problem' to 'problem as bad as it can be'; higher scores indicate greater burden. All patients (AT, PP, and PTA groups). |
| Secondary | Tonsillectomy | From enrollment to 12 months follow-up | Proportion of patients who have undergone tonsillectomy. All patients (AT, PP, and PTA groups). |
| Secondary | Pharyngeal infectious episodes | From enrollment to 12 months follow-up | Number of episodes of acute tonsillitis, peritonsillar phlegmon, and peritonsillar abscess after inclusion. All patients (AT, PP, and PTA groups). |
| Secondary | Minimal Clinically Important Difference for STAT-10 | From enrollment to day 7 | Estimated minimal clinically important difference (MCID) for the Sore Throat Assessment Tool-10 (STAT-10) in the AT and PP groups, based on changes in STAT-10 score during the first 7 days. STAT-10 consists of 10 items each rated from 1 (not at all) to 5 (to a very high degree); total score range 10-50, with higher scores indicating greater symptom burden (worse outcome). |
| Secondary | Minimal Clinically Important Difference for PTAAT-12 | From enrollment to day 7 | Estimated minimal clinically important difference (MCID) for the Peritonsillar Abscess Assessment Tool-12 (PTAAT-12) in the PTA group, based on changes in PTAAT-12 score during the first 7 days. PTAAT-12 consists of 12 items each rated from 1 (not at all) to 5 (to a very high degree); total score range 12-60, with higher scores indicating greater symptom burden (worse outcome). |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07896226/registered